Review



cluster differentiation 31 cd31  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech cluster differentiation 31 cd31
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Cluster Differentiation 31 Cd31, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 594 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cluster differentiation 31 cd31/product/Proteintech
    Average 96 stars, based on 594 article reviews
    cluster differentiation 31 cd31 - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "p16INK4a downregulation alleviates temporomandibular joint osteoarthritis combined with type 2 diabetes by driving M2 polarization."

    Article Title: p16INK4a downregulation alleviates temporomandibular joint osteoarthritis combined with type 2 diabetes by driving M2 polarization.

    Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    doi: 10.1016/j.biopha.2025.118172

    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of CD31 and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Figure Legend Snippet: Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of CD31 and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.

    Techniques Used: Cell Culture, Transwell Assay, Wound Healing Assay, Tube Formation Assay, Western Blot, Quantitative RT-PCR, Expressing, Knockdown, Control, Derivative Assay



    Similar Products

    cluster of differentiation 31 (cd31)  (Cytelligen Inc)
    90
    Cytelligen Inc cluster of differentiation 31 (cd31)
    Cluster Of Differentiation 31 (Cd31), supplied by Cytelligen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cluster of differentiation 31 (cd31)/product/Cytelligen Inc
    Average 90 stars, based on 1 article reviews
    cluster of differentiation 31 (cd31) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cluster differentiation 31 cd31  (Proteintech)
    96
    Proteintech cluster differentiation 31 cd31
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Cluster Differentiation 31 Cd31, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cluster differentiation 31 cd31/product/Proteintech
    Average 96 stars, based on 1 article reviews
    cluster differentiation 31 cd31 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    cluster of differentiation 31 cd31 antibody  (Proteintech)
    90
    Proteintech cluster of differentiation 31 cd31 antibody
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Cluster Of Differentiation 31 Cd31 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cluster of differentiation 31 cd31 antibody/product/Proteintech
    Average 90 stars, based on 1 article reviews
    cluster of differentiation 31 cd31 antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cluster of differentiation 31 (cd31) antibody  (Huabio Inc)
    90
    Huabio Inc cluster of differentiation 31 (cd31) antibody
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Cluster Of Differentiation 31 (Cd31) Antibody, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cluster of differentiation 31 (cd31) antibody/product/Huabio Inc
    Average 90 stars, based on 1 article reviews
    cluster of differentiation 31 (cd31) antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cluster differentiation 31 (cd31  (Biozol Diagnostica Vertrieb GmbH)
    90
    Biozol Diagnostica Vertrieb GmbH cluster differentiation 31 (cd31
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Cluster Differentiation 31 (Cd31, supplied by Biozol Diagnostica Vertrieb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cluster differentiation 31 (cd31/product/Biozol Diagnostica Vertrieb GmbH
    Average 90 stars, based on 1 article reviews
    cluster differentiation 31 (cd31 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cluster of differentiation 31 (cd31) af6191 antibody  (Affinity Biosciences)
    90
    Affinity Biosciences cluster of differentiation 31 (cd31) af6191 antibody
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Cluster Of Differentiation 31 (Cd31) Af6191 Antibody, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cluster of differentiation 31 (cd31) af6191 antibody/product/Affinity Biosciences
    Average 90 stars, based on 1 article reviews
    cluster of differentiation 31 (cd31) af6191 antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    cluster differentiation 31 (cd31  (Thermo Fisher)
    90
    Thermo Fisher cluster differentiation 31 (cd31
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Cluster Differentiation 31 (Cd31, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cluster differentiation 31 (cd31/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    cluster differentiation 31 (cd31 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    rat anti-cluster differentiation 31 (cd31  (Biozol Diagnostica Vertrieb GmbH)
    90
    Biozol Diagnostica Vertrieb GmbH rat anti-cluster differentiation 31 (cd31
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Rat Anti Cluster Differentiation 31 (Cd31, supplied by Biozol Diagnostica Vertrieb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti-cluster differentiation 31 (cd31/product/Biozol Diagnostica Vertrieb GmbH
    Average 90 stars, based on 1 article reviews
    rat anti-cluster differentiation 31 (cd31 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    anti‐cluster differentiation 31 (cd31  (R&D Systems Hematology)
    90
    R&D Systems Hematology anti‐cluster differentiation 31 (cd31
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Anti‐Cluster Differentiation 31 (Cd31, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti‐cluster differentiation 31 (cd31/product/R&D Systems Hematology
    Average 90 stars, based on 1 article reviews
    anti‐cluster differentiation 31 (cd31 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    anti-cluster differentiation 31 (cd31  (R&D Systems Hematology)
    90
    R&D Systems Hematology anti-cluster differentiation 31 (cd31
    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of <t>CD31</t> and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.
    Anti Cluster Differentiation 31 (Cd31, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-cluster differentiation 31 (cd31/product/R&D Systems Hematology
    Average 90 stars, based on 1 article reviews
    anti-cluster differentiation 31 (cd31 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of CD31 and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.

    Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    Article Title: p16INK4a downregulation alleviates temporomandibular joint osteoarthritis combined with type 2 diabetes by driving M2 polarization.

    doi: 10.1016/j.biopha.2025.118172

    Figure Lengend Snippet: Fig. 3. MS37452 and P16KD restrain inflammatory angiogenesis in inflammatory microenvironment of TMJ. (A) A diagram showing how to collect conditioned medium (CM) from M0. M0 cells were divided into three groups: Ctrl, P16KD, and MS37452. M0 were stimulated with or without TNFα ± GP during culture for 24 h. Next, medium was changed to fresh RPMI-1640 + 10 % FBS for 24 h and M0 CM was collected. At last, M0 CM was co-cultured with HUVECs. Then, HUVECs were used for subsequent transwell assay, scratch assay, tube formation assay, western blot and RT-qPCR. (B) Representative images and quantification of HUVECs transwell assay (Ctrl: M0 VS TNFα+GP: t = 66.86, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 77.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 65.01, df = 4). (C) Representative images and quantification of HUVECs scratch assay (Ctrl: M0 VS TNFα+GP: t = 23.12, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 23.14, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 22.50, df = 4). (D) Representative images and quantification of HUVECs tube formation assay (Ctrl: M0 VS TNFα+GP: t = 139.4, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 115.5, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 116.8, df = 4). (E) Western blot analysis of CD31 and VEGFA in HUVECs from different groups. (F) RT-qPCR analysis of CD31 and VEGFA in HUVECs from different groups (Relative expression of CD31 mRNA: Ctrl: M0 VS TNFα+GP: t = 66.96, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 80.36, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 86.18, df = 4. Relative expression of VEGFA mRNA: Ctrl: M0 VS TNFα+GP: t = 61.40, df = 4. Ctrl-TNFα+GP VS P16KD-TNFα+GP: t = 75.08, df = 4. Ctrl-TNFα+GP VS MS37452-TNFα+GP: t = 72.31, df = 4). Each experiment was performed three to five times. The data are presented as mean ± SD. P16KD, p16 knockdown; Ctrl, control; M0, human THP-1 derived macrophages; GP, high glucose and high palmitoleic acid. *P < 0.05 represent significant differences between the indi cated columns.

    Article Snippet: After that, membranes were incubated at 4 ◦C overnight with primary antibodies against inducible nitric oxide synthase (INOS) (Proteintech Group, Rosemont, IL, USA), arginase 1 (Arg1) (Proteintech Group, Rosemont, IL, USA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Proteintech Group, Rosemont, IL, USA), transferrin receptor (TFRC) (Proteintech Group, Rosemont, IL, USA), vascular endothelial growth factor A (VEGFA) (Proteintech Group, Rosemont, IL, USA), alkaline phosphatase (ALP) (Proteintech Group, Rosemont, IL, USA), runt-related transcription factor 2 (RUNX2) (Proteintech Group, Rosemont, IL, USA), cluster differentiation 31 (CD31) (Proteintech Group, Rosemont, IL, USA), ferritin heavy chain (FTH1) (Proteintech Group, Rosemont, IL, USA).

    Techniques: Cell Culture, Transwell Assay, Wound Healing Assay, Tube Formation Assay, Western Blot, Quantitative RT-PCR, Expressing, Knockdown, Control, Derivative Assay